

# Extravasation assessment and documentation tool

This assessment tool relates to the extravasation of intravenous anti-cancer therapies or contrast media.

Hospital ID: \_\_\_\_\_ MRN: \_\_\_\_\_  
 Surname: \_\_\_\_\_  
 Given names: \_\_\_\_\_  
 Date of birth: \_\_\_\_\_ Sex: \_\_\_\_\_ AMO: \_\_\_\_\_

Pronouns: \_\_\_\_\_

Preferred names: \_\_\_\_\_

## Extravasation

Date:	During administration
Time:	Immediately after administration
Drug/solution:	After administration: _____ days _____ hours
Approx. volume: _____ ml	

## Vascular access device

PIVC	PICC	TIVAD	tc-CICC	A-CICC
Insertion date: _____	Insertion time: _____	TIVAD non-coring needle: _____ mm _____ gauge		

## Administration

Free flow/gravity	Infusion pump	Syringe
-------------------	---------------	---------

## Signs and symptoms


Pain	Burning	Tingling	Stinging
Erythema	Blanching	Blister/s	Bleb formation
Swelling	Exudate	Induration	Other discolouration: _____
No blood return	Change in free flow rate	Infusion pump alarm	

## Location

### Mark affected area

Size of area:

\_\_\_\_\_ cm x \_\_\_\_\_ cm



## Immediate actions

- S** TOP injection/infusion immediately
- L** EAVE VAD in situ
- A** SPIRATE residual drug from VAD with syringe
- P** LAN next actions

## Secondary actions

Treating team notified  
 Photo taken  
 Affected area outlined with marker  
 Warm compress \_\_\_\_\_ Cold compress \_\_\_\_\_  
 Application time: \_\_\_\_\_ Frequency: \_\_\_\_\_  
 Antidote: \_\_\_\_\_ Time: \_\_\_\_\_  
 Analgesia: \_\_\_\_\_ Time: \_\_\_\_\_

Patient education	Discharge
Extravasation details	Take home medications (analgesia, creams)
Post-acute management	Follow-up appointments
Written information	Admission

Referral/follow-up appointments	
Dermatology _____	Community _____
Plastics _____	Cancer care _____
Surgical _____	Other _____

Details of person reporting extravasation	
Name _____	Designation _____
Signature _____	Date/time _____

**Extravasation assessment** - to complete this assessment please consult the grading scale provided below

Day					
Date					
Skin colour					
Skin temp.					
Skin integrity					
Oedema					
Mobility					
Pain					
Systemic temp.					
Photo					
Signature					

Grading scale	0	1	2	3	4
Skin colour	Normal	Pink	Red	Blanched	Blackened
Skin temp.	Normal	Warm	Hot		
Skin integrity	Unbroken	Blistered	Superficial skin loss	Tissue loss exposing subcutaneous tissue	Tissue loss exposing muscle or bone, deep crater or necrosis
Oedema	Absent	Non-pitting	Pitting		
Mobility	Full	Slightly limited	Very limited	Immobile	
Pain	Grade using a scale of 0-10: 0=no pain 10=worse pain				
Systemic temp.	Normal	Elevated			

#### References

- Mader, I., P. Furst-Weger, R.M. Mader et al. 2010. "Extravasation of Cytotoxic Agents: Compendium for Prevention and Management." 2nd Ed. Springer-Verlag, Vienna.
- Polovich, M., M. Olsen, K. LeFebvre. 2014. "Chemotherapy and Biotherapy Guidelines and Recommendations for Practice" 4th ed. Oncology Nursing Society. Pittsburgh.
- Schulmeister, L. 2011. "Extravasation management: clinical update". Semin Oncol Nurs 27(1):82-90.
- Kim, J. T., J. Y. Park, H. J. Lee et al. 2020. "Guidelines for the management of extravasation". J Educ Eval Health Prof 17:21.
- Ding, S., N. R. Meystre, C. Campeanu, et al. 2018. "Contrast media extravasations in patients undergoing computerized tomography scanning: a systematic review and meta-analysis of risk factors and interventions." JBI Database System Rev Implement Rep 16(1):87-116.

E: [feedback@eviq.org.au](mailto:feedback@eviq.org.au)  
W: [eviq.org.au](http://eviq.org.au)

© Cancer Institute NSW. Version 6. Last reviewed May 2023. This document reflects what is currently regarded as safe practice. While every effort has been made to ensure the accuracy of the contents at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury, or expense arising from any such errors or omission in the contents of this work. Any reference throughout the document to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. See [www.eviq.org.au](http://www.eviq.org.au) for our full disclaimer and any updates.

